VEGF-C156S delivery through the CCA immediately after tMCAO does not influence lymphatic vessel area at COS, SSS, and dCLN. (A–C) IHC sections of COS of dural lymphatic vessels (A), SSS of dural lymphatic vessels (B), and sections of dCLN (C) were stained with Lyve-1 fluorescent antibody after either control or VEGF-C156S treatment of tMCAO mice. Representative confocal images of lymphatic vessels near COS and SSS of dura and dCLN. Quantitation of each image (n = 3 mice per group; mean ± SEM, unpaired Student’s t test). Scale bars = 500 µm for COS and SSS of dural lymphatic vessels and 100 µm for dCLN. (D) Quantitation of number of loops, sprouts, and vessel length near the cribriform in untreated and VEGF-C–treated tMCAO mice at day 7 (n = 3 mice per group; mean ± SEM, unpaired Student’s t test). (E) Quantitation of number of loops, sprouts, and lymphatic vessel diameter near the dural COS in untreated and VEGF-C–treated tMCAO mice at day 7 (n = 3 mice per group; mean ± SEM, unpaired Student’s t test). (F) Quantitation of number of loops, sprouts, and lymphatic vessel diameter near the dural SSS in untreated and VEGF-C–treated tMCAO mice at day 7 (n = 3 mice per group; mean ± SEM, unpaired Student’s t test). Source data are available for this figure: SourceData FS5.